KATHERINE EBAN is an investigative reporter whose articles on pharmaceutical counterfeiting, gun trafficking, and coercive CIA interrogations, have won international attention and numerous awards. She is currently a Fortune magazine Contributor, and has also written for Vanity Fair, Self, The Nation and other publications. She formerly worked as a reporter for the New York Times and the New York Observer. Her work has been featured on national news programs including 60 Minutes, Nightline and 20/20. read more

WYSIWYG region 1

In the tradition of the great investigative classics, Dangerous Doses exposes the dark side of America’s pharmaceutical trade. Stolen, compromised, and counterfeit medicine increasingly makes its way into a poorly regulated distribution system, where it reaches unsuspecting patients who stake their lives on its effectiveness. Tragically, we cannot trust the purity of the costly drugs supplied by our most reputable drugstore and hospital pharmacies. read more

icon_bandnPurchase the book at Barnes & Noble.

icon_amazonPurchase the book on Amazon.

  • Deadline Club Awards

    Katherine's article, "Dirty Medicine," which ran last May on Fortune.com, won the 2014 Deadline Club Business Investigative Reporting award and was a finalist for the public service award. Read more
  • “Drug Shortages: The Scary Reality of a World Without Meds,” Reader’s Digest

    Imagine surgeons running out of anesthetic drugs, cancer patients who can't get lifesaving chemotherapy, and doctors scrambling for the most basic antibiotics. We're already there. Read more
  • 2014 National Magazine Awards

    Katherine's article "Dirty Medicine," which ran last May on Fortune.com, was named a finalist in the Public Interest category of The American Society of Magazine Editors' 2014 National Magazine Awards. Read more
  • “What ails Big Pharma,” Fortune Magazine

    A new book chronicles the uneasy relationship between money and drugs, and what it means for the rest of us. Read more
  • “Ranbaxy’s empty promises,” Fortune Magazine

    On Jan. 23, the FDA dropped a heavy hammer on the Indian generic drug giant Ranbaxy Laboratories, announcing it will restrict imports from the company's manufacturing plant in Toansa, India. It was the fourth Ranbaxy factory to be barred by the FDA since 2008. The move came after an unannounced inspection in early January turned up a devastating litany of infractions: a laboratory area littered with flies, a leaking refrigerator for drug samples, and evidence that laboratory technicians were altering data to improve test results. Read more